Meanwhile, the CSGALNACT2 expression was positively associated with the level of immune cells, and high expression of CSGALNACT2 was significantly associated with shorter overall survival (OS) rate in colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) [23]. Here, CSGALNACT2 is linked to colon adenocarcinoma.